Based on the DRI Healthcare Trust stock forecast from 7 analysts, the average analyst target price for DRI Healthcare Trust is CAD 20.81 over the next 12 months. DRI Healthcare Trust’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of DRI Healthcare Trust is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, DRI Healthcare Trust’s stock price was CAD 17.00. DRI Healthcare Trust’s stock price has changed by -0.87% over the past week, +6.25% over the past month and +122.22% over the last year.
No recent analyst target price found for DRI Healthcare Trust
No recent average analyst rating found for DRI Healthcare Trust
Company Overview DRI Healthcare Trust
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada. Address: 100 King Street West, Toronto, ON, Canada, M5X 1B1 Read Less
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headq...Read More
Frequently Asked Questions About DRI Healthcare Trust (DHT-UN:CA) Stock
Based on ratings from 7 analysts DRI Healthcare Trust's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 13 buy, sell and hold ratings.
DHT-UN:CA stock's dividend yield is 2.65%.
Our analysis grades DHT-UN:CA stock's dividend yield at F. This means that DHT-UN:CA stock's dividend yield is above 33% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSX exchange.
Based on this DHT-UN:CA may be a poor dividend stock for its sector.
Based on targets from 7 analysts, the average taret price for DHT-UN:CA is CAD 20.81 over the next 12 months. The maximum analyst target price is CAD 24 while the minimum anlayst target price is CAD 11.5.
DHT-UN:CA stock's Price/Earning ratio is 6.08.
Our analysis grades DHT-UN:CA stock's Price / Earning ratio at C-. This means that DHT-UN:CA stock's Price/Earning ratio is above 29% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSX exchange.
Based on this DHT-UN:CA may be undervalued for its sector.
The last closing price of DHT-UN:CA's stock was CAD 17.00.
The most recent market capitalization for DHT-UN:CA is CAD 0.97B.
Based on targets from 7 analysts, the average taret price for DHT-UN:CA is projected at CAD 20.81 over the next 12 months.
This means that DHT-UN:CA's stock price may go up by +22.40% over the next 12 months.
We can't find any ETFs which contains DRI Healthcare Trust's stock.
As per our most recent records DRI Healthcare Trust has 0 Employees.
DRI Healthcare Trust's registered address is 1 First Canadian Place, Toronto, ON, Canada, M5X 1B1.
You can get more information about it from DRI Healthcare Trust's website at https://www.dricapital.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DHT-UN:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
